Literature DB >> 21268072

Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP.

Jia Wang1, Qing Zhao, Qi Qi, Hong-yan Gu, Jing-jing Rong, Rong Mu, Mei-juan Zou, Lei Tao, Qi-dong You, Qing-long Guo.   

Abstract

As an oncoprotein, mutant p53 is a potential tumor-specific target for cancer therapy. Most mutated forms of the protein are largely accumulated in cancer cells due to their increased stability. In the present study, we demonstrate that mutant p53 protein stability is regulated by gambogic acid (GA). Following GA exposure, protein levels of mutant p53 decreased while the mRNA levels were not affected in MDA-MB-435 cells, which indicate that GA down-regulates mutant p53 at post-transcription level. Co-treatment with GA and cycloheximide, a protein synthesis inhibitor, induced a decrease of half-life of mutant p53 protein. These findings indicated that the reduction of mutant p53 by GA was due to the destabilization and degradation of the protein. Furthermore, inhibition of proteasome activity by MG132 blocked GA-induced down-regulation of mutant p53, causing mutant p53 accumulation in detergent-insoluble cellular fractions. Further studies revealed that mutant p53 was ubiquitinated and it was chaperones related ubiquitin ligase carboxy terminus of Hsp70-interacting protein (CHIP) rather than MDM2 involved in the degradation of mutant p53. In addition, GA prevented Hsp90/mutant p53 complex formation and enhanced interaction of mutant p53 with Hsp70. Depletion of CHIP stabilized mutant p53 in GA treated cells. In conclusion, mutant p53 may be down-regulated by GA through chaperones-assisted ubiquitin/proteasome degradation pathway in cancer cells.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268072     DOI: 10.1002/jcb.22941

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

1.  Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.

Authors:  Adeline Péchery; Sylvie Fauconnet; Hugues Bittard; Isabelle Lascombe
Journal:  Tumour Biol       Date:  2016-09-16

2.  It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Authors:  Ian M Love; Steven R Grossman
Journal:  Genes Cancer       Date:  2012-03

3.  Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Authors:  Shengliang Zhang; Lanlan Zhou; Bo Hong; A Pieter J van den Heuvel; Varun V Prabhu; Noel A Warfel; Christina Leah B Kline; David T Dicker; Levy Kopelovich; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

Review 4.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

Review 5.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

Review 6.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

Review 7.  Should mutant TP53 be targeted for cancer therapy?

Authors:  Andreas Strasser; Gemma L Kelly; Zilu Wang
Journal:  Cell Death Differ       Date:  2022-03-24       Impact factor: 12.067

8.  MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP.

Authors:  Zhe Cao; Jianwei Xu; Hua Huang; Peng Shen; Lei You; Li Zhou; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 9.  Targeting Oncogenic Mutant p53 for Cancer Therapy.

Authors:  Alejandro Parrales; Tomoo Iwakuma
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

Review 10.  A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging?

Authors:  Vibhuti Joshi; Ayeman Amanullah; Arun Upadhyay; Ribhav Mishra; Amit Kumar; Amit Mishra
Journal:  Front Mol Neurosci       Date:  2016-10-04       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.